Jones Pamela S, Aghi Manish K, Muzikansky Alona, Shih Helen A, Barker Fred G, Curry William T
Department of Neurosurgery, Stephen L. Harris Center for Chordoma Care, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E-9026, Boston, MA 02114, USA.
Department of Neurosurgery, University of California, San Francisco, 5 San Francisco, CA, USA.
J Clin Neurosci. 2014 Sep;21(9):1490-6. doi: 10.1016/j.jocn.2014.02.008. Epub 2014 May 19.
This study aims to demonstrate survival rates and treatment patterns among patients with chordomas of the skull base using a large population database. Patients with cranial chordomas between 1973 and 2009 were identified from the USA Surveillance, Epidemiology, and End Results (SEER) public use database. Kaplan-Meier analysis was used to examine the effect of surgery and radiation on overall survival. We identified 394 patients with histologically-confirmed cranial chordomas. Median survival was 151 months. Most patients (89.09%) underwent surgery. Less than half (44.92%) received radiation after diagnosis. Patients who underwent surgical resection survived significantly longer than those who did not undergo resection, regardless of other treatments (151 versus 81 months, p<0.001). Ten year survival was lower among patients receiving radiation (44.8% versus 61.4%, p=0.66). Surgery predicted better overall survival by univariate analysis (hazard ratio [HR] 0.603, p=0.0293); younger age at diagnosis (HR 1.028, p<0.001), and later year of diagnosis (HR 0.971, p=0.0027) were prognostic of improved survival in a multivariate model. In subgroup analysis of patients with documented tumor size, smaller tumor size (HR 1.021, p=0.0067), younger age (HR 1.031, p=0.001), and treatment within a higher volume registry (HR 0.490, p=0.0129) predicted improved survival. Surgical intervention offers survival benefit for cranial chordomas. Findings of decreased survival in patients receiving radiation may be associated with selection. Studies examining surgical extent of resection data and radiation details are needed to determine the impact of radiotherapy.
本研究旨在利用一个大型人口数据库来展示颅底脊索瘤患者的生存率和治疗模式。1973年至2009年间的颅脊索瘤患者是从美国监测、流行病学和最终结果(SEER)公共使用数据库中识别出来的。采用Kaplan-Meier分析来检验手术和放疗对总生存期的影响。我们识别出394例经组织学确诊的颅脊索瘤患者。中位生存期为151个月。大多数患者(89. .09%)接受了手术。不到一半(44.92%)的患者在诊断后接受了放疗。接受手术切除的患者比未接受切除的患者存活时间显著更长,无论其他治疗情况如何(151个月对81个月,p<0.001)。接受放疗的患者10年生存率较低(44.8%对61.4%,p = 0.66)。单因素分析显示手术可预测更好的总生存期(风险比[HR] 0.603,p = 0.0293);在多变量模型中,诊断时年龄较小(HR 1.028,p<0.001)和诊断年份较晚(HR 0.971,p = 0.0027)是生存期改善的预后因素。在有记录肿瘤大小的患者亚组分析中,肿瘤较小(HR 1.021,p = 0.0067)、年龄较小(HR 1.031,p = 0.001)以及在更高容量登记处接受治疗(HR 0.490,p = 0.0129)可预测生存期改善。手术干预对颅脊索瘤有生存获益。接受放疗患者生存率降低的发现可能与选择有关。需要研究手术切除范围数据和放疗细节以确定放疗的影响。